1. Home
  2. |Insights
  3. |Here We Go Again: DFARS Changes to the "Only One Offer" Rule

Here We Go Again: DFARS Changes to the "Only One Offer" Rule

Client Alert | 1 min read | 07.30.19

As we noted in a recent post, for several years, the Defense Federal Acquisition Regulation Supplement (DFARS) has contained a rule at DFARS 215.371-3(a) that if only one offer is received, even if submitted with the expectation of competition, the adequate price competition exception from the requirement to submit certified cost or pricing data does not apply unless an official at a level above the Contracting Officer (CO) approves the determination that the price is reasonable. On June 28, 2019, DoD issued a final rule to implement Section 822 of the Fiscal Year 2017 National Defense Authorization Act, which eliminates DFARS 215.371-3(a) and, thus, the applicability of the adequate price competition exception under FAR 15.403-1(b)(1) to single-offer situations. The rule also, among other things:

  • Streamlines the existing requirements at DFARS 215.371-3(b), with additional emphasis on the requirement to obtain certified cost or pricing data when only one offer is received; and
  • Imposes responsibility on offerors for determining whether a subcontractor qualifies for an exception from the certified cost or pricing data requirement on the basis of adequate competition.

On July 16, 2019, DoD issued minor technical corrections to the rule, which is effective July 31, 2019.

Insights

Client Alert | 6 min read | 04.29.26

CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)

On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies....